Abstract:Background: A malignant tumor's immune environment, including infiltrating immune cell status, can be critical to patient outcomes. Recent studies have shown that immune cell infiltration (ICI) in pancreatic cancer (PC) is highly correlated with the response to immunotherapy and patient prognosis. Therefore, we aimed to create an ICI score that accurately predicts patient outcomes and immunotherapeutic efficacy. Methods: The ICI statuses of patients with PC were estimated from the publicly available The Cancer Genome Atlas (TCGA) pancreatic ductal adenocarcinoma and GSE57495 gene expression datasets using two computational algorithms (CIBERSORT and ESTIMATE). ICI and transcriptome subsets were defined using a clustering algorithm, and survival analysis was also performed. Principal component analysis was used to calculate the novel ICI score, and gene set enrichment analysis was performed to identify the pathways underlying the defined clusters. The tumor mutational burden (TMB) was further explored in TCGA cohort, and survival analysis was used to assess the capability of the ICI and TMB scores to predict overall survival. Additionally, common driver gene mutations and their differential expression in the different ICI score group were investigated. Results: The ICI landscapes of 240 patients were generated using the devised algorithm, revealing three ICI and three gene clusters whose use improved the prediction of overall survival (p = 0.019 and p < 0.001, respectively). Crucial immune checkpoint genes were differentially expressed among these subtypes; the RIG-I-LIKE and NOD-LIKE receptor signaling pathways were enriched in samples with low ICI scores (p < 0.05). We also found that the TMB scores could predict survival outcomes, whereas the ICI scores also could predict prognoses independent of TMB. Notably, ICI scores could effectively predict responses to immunotherapy. KRAS, TP53, CDKN2A, SMAD4 and TTN remained the most commonly mutated genes in PC; moreover, KRAS and TP53 mutation rates were significantly different between the two ICI score groups. Conclusions: We developed a novel ICI score that could independently predict the response to immunotherapy and survival of patients with PC. Evaluation of the ICI landscape in a larger cohort could clarify the interactions between these infiltrating cells, the tumor microenvironment and response to immunotherapy. Lay abstract Pancreatic cancer (PC) is a lethal malignancy with a higher mortality rate. Currently, immunotherapy is increasingly interesting to clinical researchers and considered a novel and efficient treatment. However, in clinical practice, immunotherapy has not demonstrated consistent therapeutic responses across all patients. Thus, to identify the immunotherapy-sensitive subgroup of advanced PC patients is important based on immune cell infiltration. In this study, we downloaded and processed transcriptomic data from TCGA-PAAD and GEO databases and used CIBERSORT and ESTIMATE algorithms to reveal the immune cell infiltration landscape of pancreatic cancer. According to consensus clustering results, we identified three ICI and gene clusters for guiding the identification of immune-subtype in future clinical treatments. Finally, we calculated an ICI score for each subject to describe their tumor immune landscape and performed the risk grouping for all patients and multiomics analysis. In sum, the ICI score and clusters could be used in the future to assist clinicians in identifying patients with the greatest chance of responding to immunotherapy.

An Integrated Multi-Omics Analysis Identifying Immune Subtypes of Pancreatic Cancer

Integrated multi-omics identified the novel intratumor microbiome-derived subtypes and signature to predict the outcome, tumor microenvironment heterogeneity, and immunotherapy response for pancreatic cancer patients

Identification of a Novel Immune-Related Prognostic Model for Patients with Colorectal Cancer Based on 3 Subtypes.

Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy

Identification of Prognosis-Related Molecular Subgroups and Construction of a Prognostic Prediction Model Using Immune-Related Genes in Pancreatic Cancer

Bioinformatics-Based Identification of Tumor Microenvironment-Related Prognostic Genes in Pancreatic Cancer

Identification of the Immune Cell Infiltration Landscape in Pancreatic Cancer to Assist Immunotherapy.

Immune Profiling and Prognostic Model of Pancreatic Cancer Using Quantitative Pathology and Single-Cell RNA Sequencing.

PANoptosis-related molecular subtype and prognostic model associated with the immune microenvironment and individualized therapy in pancreatic cancer

Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes

Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy

Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification

Integrative Analysis Reveals Clinically Relevant Molecular Fingerprints in Pancreatic Cancer

Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes.

Tumor Microenvironment Characteristics of Pancreatic Cancer to Determine Prognosis and Immune-Related Gene Signatures

Single-Cell Transcriptomic Analysis of Tumor-Immune Microenvironment in Pancreatic Cancer

Development and Validation of Novel Microenvironment-Based Immune Molecular Subtypes of Breast Cancer: Implications for Immunotherapy.

An Accurate Prognostic Model and Treatment for Pancreatic Carcinoma Based on the Tumor Immune Microenvironment

Identification of immune-related subtypes of colorectal cancer to improve antitumor immunotherapy

Definition of immune molecular subtypes with distinct immune microenvironment, recurrence, and PANoptosis features to aid clinical therapeutic decision-making

Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer